FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 308 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR How to Safely Keep Up With Your Cancer Screening and Care... December 10, 2020 Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small... November 21, 2020 Aspartame and cancer – sweet nothings? July 14, 2023 New on NCI’s Websites for September 2021 September 1, 2021 Load more HOT NEWS FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer New on NCI’s Websites for September 2020 A winding journey into the world of children’s and young people’s... A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is...
